Sugi Predict

Sugi Predict / Compounds / SCHEMBL2649031

SCHEMBL2649031

SCHEMBL2649031

O=[N+]([O-])c1cccc(-c2ccncc2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.64
▸ NPC1 O15118 2/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ CYP2C9 P11712 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ LMNA P02545 3/20 0.57
▸ TSHR P16473 1/20 0.57
▸ CDC7 O00311 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ IDO1 P14902 1/20 0.51
▸ ABL1 P00519 1/20 0.51
▸ BCR P11274 1/20 0.51
▸ PRKCA P17252 1/20 0.51
▸ BCHE P06276 1/20 0.51
▸ MGAM O43451 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ SI P14410 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27579962 0.98 NPC1 (0.62) MAPTNPC1RAB9ACYP1A2CYP3A4
Hydrochloric Acid SCHEMBL9528174 0.98 NPC1 (0.62) MAPTNPC1RAB9ACYP1A2CYP3A4
SCHEMBL6738366 0.86 TSHR (0.76) MAPTNPC1RAB9ALMNATSHR
SCHEMBL29526232 0.84 TSHR (0.67) MAPTNPC1RAB9ALMNATSHR
SCHEMBL2009026 0.84 TSHR (0.67) MAPTNPC1RAB9ALMNATSHR
SCHEMBL28471286 0.84 TSHR (0.73) MAPTNPC1RAB9ALMNATSHR
Iodide SCHEMBL30804629 0.84 TSHR (0.73) MAPTNPC1RAB9ALMNATSHR
Iodide SCHEMBL28598177 0.84 TSHR (0.73) MAPTNPC1RAB9ALMNATSHR
SCHEMBL11392466 0.84 TSHR (0.73) MAPTNPC1RAB9ALMNATSHR
SCHEMBL11392461 0.84 TSHR (0.73) MAPTNPC1RAB9ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0176956-B1 Diaryl derivatives BYK GULDEN LOMBERG CHEM FAB (DE) 1994-06-15 — — EP claimed
US-4008239-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1977-02-15 — — US claimed
US-3994903-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1976-11-30 — — US claimed
US-20250250233-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE PRILENIA NEUROTHERAPEUTICS LTD. (IL) 2025-08-07 — — US disclosed
US-12358869-B2 Diarylureas as CB1 allosteric modulators RESEARCH TRIANGLE INSTITUTE 2025-07-15 — — US disclosed
EP-4519246-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE Prilenia Neurotherapeutics Ltd. (IL) 2025-03-12 — — EP disclosed
CN-119137100-A Process and intermediates for the preparation of pridopidine 普瑞尼亚神经治疗有限公司 2024-12-13 — — CN disclosed
WO-2023214412-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE PRILENIA NEUROTHERAPEUTICS LTD. (IL) 2023-11-09 — — WO disclosed
US-20230212147-A1 ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Hongyun Biotech Co., Ltd. (CN) 2023-07-06 — — US disclosed
CN-116283668-A Diaryl ureas as CB1 allosteric modulators 研究三角协会 2023-06-23 — — CN disclosed
WO-2023011610-A1 BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 南京红云生物科技有限公司 2023-02-09 — — WO disclosed
US-4055588-A Tetra-(lower-alkyl)3-(3-nitrophenyl)-1,5-pentanedione-1,2,4,5-tetracarboxylates STERLING DRUG INC. (US) 1977-10-25 — — US disclosed
US-4008239-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1977-02-15 — — US disclosed
US-4008239-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1977-02-15 — — US disclosed
US-3994903-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1976-11-30 — — US disclosed
US-3994903-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1976-11-30 — — US disclosed
US-3994903-A Preparation of 4-(3-nitrophenyl)pyridine STERLING DRUG INC. (US) 1976-11-30 — — US disclosed
US-3970662-A 4-(3-Nitrophenyl)-2,3,5,6-pyridinetetracarboxylic acid and intermediates STERLING DRUG INC. (US) 1976-07-20 — — US disclosed
US-3970662-A 4-(3-Nitrophenyl)-2,3,5,6-pyridinetetracarboxylic acid and intermediates STERLING DRUG INC. (US) 1976-07-20 — — US disclosed
US-3922278-A 4-(3-Nitrophenyl)-3,5-pyridinedicarboxylic acid STERLING DRUG INC 1975-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212147-A1 ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF WEE1, EGFR, WEE2 MAPT 2939/4885NPC1 1022/4885RAB9A 4178/4885
US-12358869-B2 Diarylureas as CB1 allosteric modulators CNR1, CNR2, GPR18 MAPT 2523/4885NPC1 1047/4885RAB9A 857/4885
US-20250250233-A1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE QDPR, MAOB, DRD2 MAPT 1794/4885NPC1 2605/4885RAB9A 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.